Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders

NCT03344419 is registered in ClinicalTrials.gov with New York State Psychiatric Institute as lead sponsor.

NCT NCT03344419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03344419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
Lead sponsor
New York State Psychiatric Institute
Phase
Phase 3
Overall status
Suspended
Start date
October 1, 2017
Completion date
December 31, 2024
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cocaine use disorder